Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
Refractory NPM1-Mutated
.
Show all posts
Showing posts with label
Refractory NPM1-Mutated
.
Show all posts
Tuesday, July 28, 2026
FDA Approves Komzifti (ziftomenib) for the Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
›
Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) announced the U.S. Food and Drug Administration (FDA) approval o...
›
Home
View web version
